Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $5,948,058.96 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 84,948 shares of Tempus AI stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $70.02, for a total value of $5,948,058.96. Following the completion of the transaction, the chief executive officer now owns 5,208,057 shares in the company, valued at $364,668,151.14. The trade was a 1.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tempus AI Price Performance

Tempus AI stock opened at $89.44 on Monday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a 50 day moving average of $46.60 and a 200-day moving average of $50.37.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Comerica Bank grew its position in shares of Tempus AI by 342.5% in the 4th quarter. Comerica Bank now owns 112,145 shares of the company’s stock worth $3,786,000 after acquiring an additional 86,800 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in Tempus AI during the fourth quarter worth $348,000. Mission Creek Capital Partners Inc. acquired a new position in Tempus AI in the fourth quarter worth $1,612,000. Oxford Asset Management LLP bought a new stake in Tempus AI during the fourth quarter valued at $457,000. Finally, Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Tempus AI during the fourth quarter worth $775,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TEM. Bank of America lifted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.